China SXT Pharmaceuticals (SXTC) Competitors $1.58 -0.12 (-7.06%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SXTC vs. PRPH, SLXN, BFRI, OMGA, MYNZ, AIM, GNPX, LIPO, AYTU, and APLMShould you be buying China SXT Pharmaceuticals stock or one of its competitors? The main competitors of China SXT Pharmaceuticals include ProPhase Labs (PRPH), Silexion Therapeutics (SLXN), Biofrontera (BFRI), Omega Therapeutics (OMGA), Mainz Biomed (MYNZ), AIM ImmunoTech (AIM), Genprex (GNPX), Lipella Pharmaceuticals (LIPO), Aytu BioPharma (AYTU), and Apollomics (APLM). These companies are all part of the "pharmaceutical products" industry. China SXT Pharmaceuticals vs. ProPhase Labs Silexion Therapeutics Biofrontera Omega Therapeutics Mainz Biomed AIM ImmunoTech Genprex Lipella Pharmaceuticals Aytu BioPharma Apollomics ProPhase Labs (NASDAQ:PRPH) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, community ranking, profitability, dividends, earnings and media sentiment. Which has stronger earnings and valuation, PRPH or SXTC? China SXT Pharmaceuticals has lower revenue, but higher earnings than ProPhase Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProPhase Labs$6.77M2.07-$16.78M-$1.26-0.27China SXT Pharmaceuticals$1.82M0.63-$3.10MN/AN/A Is PRPH or SXTC more profitable? China SXT Pharmaceuticals has a net margin of 0.00% compared to ProPhase Labs' net margin of -217.64%. China SXT Pharmaceuticals' return on equity of 0.00% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets ProPhase Labs-217.64% -62.92% -30.22% China SXT Pharmaceuticals N/A N/A N/A Which has more volatility and risk, PRPH or SXTC? ProPhase Labs has a beta of -0.56, indicating that its stock price is 156% less volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Do institutionals & insiders hold more shares of PRPH or SXTC? 9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 20.7% of ProPhase Labs shares are held by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in PRPH or SXTC? ProPhase Labs received 32 more outperform votes than China SXT Pharmaceuticals when rated by MarketBeat users. However, 61.65% of users gave China SXT Pharmaceuticals an outperform vote while only 48.93% of users gave ProPhase Labs an outperform vote. CompanyUnderperformOutperformProPhase LabsOutperform Votes11448.93% Underperform Votes11951.07% China SXT PharmaceuticalsOutperform Votes8261.65% Underperform Votes5138.35% Does the media refer more to PRPH or SXTC? In the previous week, China SXT Pharmaceuticals had 2 more articles in the media than ProPhase Labs. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 1 mentions for ProPhase Labs. ProPhase Labs' average media sentiment score of 0.98 beat China SXT Pharmaceuticals' score of 0.00 indicating that ProPhase Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProPhase Labs 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive China SXT Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryChina SXT Pharmaceuticals beats ProPhase Labs on 7 of the 13 factors compared between the two stocks. Get China SXT Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SXTC vs. The Competition Export to ExcelMetricChina SXT PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.12M$6.57B$5.40B$7.67BDividend YieldN/A3.21%5.44%4.33%P/E RatioN/A7.1022.2118.28Price / Sales0.63264.35392.73105.58Price / CashN/A65.6738.2034.62Price / Book0.056.416.774.22Net Income-$3.10M$142.49M$3.21B$247.51M7 Day Performance-27.08%7.48%4.85%5.53%1 Month Performance-43.95%-8.13%-6.31%-4.21%1 Year Performance-81.60%-1.58%16.24%4.44% China SXT Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SXTCChina SXT Pharmaceuticals0.2936 of 5 stars$1.58-7.1%N/A-80.1%$1.14M$1.82M0.0090News CoveragePRPHProPhase Labs0.8785 of 5 stars$0.30-2.3%N/A-93.2%$7.20M$6.77M-0.24130SLXNSilexion TherapeuticsN/A$0.85+0.8%$5.00+486.8%N/A$7.17MN/A0.00N/ANews CoverageGap DownBFRIBiofrontera2.7753 of 5 stars$0.80-4.6%$7.00+773.9%-45.9%$7.11M$37.32M-0.3570Positive NewsOMGAOmega Therapeutics1.8336 of 5 stars$0.13-21.8%$9.20+7,260.0%-94.7%$6.92M$8.10M-0.09120Gap UpMYNZMainz Biomed1.6908 of 5 stars$3.37+1.2%$14.00+315.4%-90.9%$6.74M$893,991.00-0.0530Positive NewsAIMAIM ImmunoTech1.8867 of 5 stars$0.09-22.3%$2.75+2,908.8%-78.0%$6.61M$170,000.00-0.1920Gap DownHigh Trading VolumeGNPXGenprex4.396 of 5 stars$0.26-0.8%$10.00+3,680.7%-89.9%$6.39MN/A0.0020News CoveragePositive NewsLIPOLipella Pharmaceuticals2.032 of 5 stars$2.45+0.4%N/A-57.2%$6.25M$536,357.00-0.584News CoverageGap DownAYTUAytu BioPharma1.0952 of 5 stars$1.00-3.7%N/A-60.9%$6.17M$77.23M-0.69160APLMApollomics1.6393 of 5 stars$5.63-5.4%$200.00+3,452.4%-87.1%$6.12M$1.22M0.0045Positive NewsGap Up Related Companies and Tools Related Companies ProPhase Labs Alternatives Silexion Therapeutics Alternatives Biofrontera Alternatives Omega Therapeutics Alternatives Mainz Biomed Alternatives AIM ImmunoTech Alternatives Genprex Alternatives Lipella Pharmaceuticals Alternatives Aytu BioPharma Alternatives Apollomics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SXTC) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Collapse Is Already HereWhen a system is about to fail, those trained to spot it often notice before anyone else. Tim Plaehn flew high...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China SXT Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China SXT Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SXTC Stock Free SXTC Stock Alerts